M alaria caused by Plasmodium falciparum (''malignant malaria'') is one of the most devastating pathogens of humans (1) . Plasmodium reichenowi, which infects chimpanzees and gorillas, is the closest relative of P. falciparum (2) . In early 20th-century experiments (never to be replicated), blood from P. reichenowi-infected chimpanzees was injected into humans, but failed to produce infections (3) . Conversely, chimpanzees injected with P.falciparuminfected human blood suffered no infection. Taken together, these data suggested that each parasite had coevolved with its host, but did not rule out chimpanzee to human transmission, or vice versa. In this issue of PNAS, Rich et al. (4) provide an answer to this malignant malaria ''mystery'' and confirm a prediction that we and our colleagues made earlier (5) .
Several Anopheles mosquito species mediate the P. falciparum life cycle (6, 7) . After an infected mosquito bite, the injected sporozoites infect host liver cells, generating merozoites that invade circulating erythrocytes (RBCs). Bouts of high fever follow when merozoites undergo cycles of asexual reproduction in RBCs. P. falciparum expresses multiple binding proteins that recognize specific targets on RBCs.* The major targets are terminal sialic acids (Sias) on O-linked glycan chains attached to glycophorins, the most abundant RBC surface glycoproteins. Although Siaindependent RBC invasion is known (8) , most field isolates exhibit Sia dependency for RBC binding (9) .
Sias are a family of sugars found at the outer termini of cell surface glycan chains of all cells of all vertebrates (10) . Although Sias appear essential for development, they are also targets for many pathogens (10) . Thus, the host ''sialome'' must constantly evolve to evade rapidly evolving pathogens. For example, an Alu-mediated exon deletion in the CMAH gene occurred Ϸ2 million to 3 million years ago in human ancestors, eventually eliminating biosynthesis of a common mammalian Sia called Nglycolylneuraminic acid (Neu5Gc) and causing accumulation of its precursor N-acetylneuraminic acid (Neu5Ac) (10 Lack of genetic diversity among P. falciparum strains (11) suggests an origin as recent as the Neolithic transition Ϸ10,000 years ago, when human farming practices augmented mosquito habitats near humans, with human settlement patterns favoring efficient transmission. In keeping with this notion, the main vector species complex Anopheles gambiae apparently evolved strong ''anthropophily'' and domesticity only since the Neolithic (7). We summarize all of these considerations in Fig. 1 and add some further speculations.
Until now, only one isolate of P. reichenowi had been sequenced. Recent sequences from two Plasmodium strains from pet chimpanzees in Gabon (12) indicated substantial divergence from the known P. reichenowi strain, suggesting a new species. Rich et al. (4) provide new data on chimpanzee malaria diversity, presenting DNA sequences Author contributions: A.V. and P.G. wrote the paper.
The authors declare no conflict of interest.
See companion article on page 14902. 1 To whom correspondence may be addressed. E-mail: a1varki@ucsd.edu or pgagneux@ucsd.edu. *We avoid the terms ''receptor'' and ''ligand,'' because of confusion about their meanings. We instead use ''target'' for the entity on the host cell that is recognized and ''binding protein'' for the pathogen protein that mediates target recognition. (4) conclude that all known P. falciparum strains arose from one of the many strains of P. reichenowi, i.e., a single chimpanzee to human transmission likely gave rise to P. falciparum. Recent studies suggest the emergence of Sia-independent targets for P. falciparum (8), which is not surprising for a rapidly evolving pathogen spreading in epidemic proportions. Most such studies, however, are done in static ex vivo systems, involving long exposure times of merozoites to RBCs. This methodology can be misleading and does not rule out that Sias are still important for initial recognition phases in vivo. Regardless, this phenomenon may represent an ominous new phase in the ongoing ''arms race'' between this very successful pathogen and the human host.
Environmental factors may have been equally important. Chimpanzees sleep in tree nests in different locations daily, and adults sleep several meters apart. In contrast, humans have used permanent shelters and slept at higher densities since the Neolithic. Given the impact of P. falciparum on mosquito feeding, favoring blood meals from multiple hosts (6), these novel human behaviors would have amplified secondary infection rates among Neolithic humans and further favored greater virulence of the humanadapted P. falciparum. The young age of human genetic variants in genes such as glucose 6-phosphate dehydrogenase or hemoglobin, which convey partial resistance to malignant malaria, is a further indication of how recent the epidemic P. falciparum is in our species (13) .
More work is needed to dissect the scenario in Fig. 1 . For example, the Siadependent binding proteins of P. falciparum and P. reichenowi other than EBA-175 are predicted to prefer Neu5Ac and Neu5Gc targets, respectively, and optimal recognition will likely require specific presentations on different glycophorins. Also, given the high frequency of positive PCR results (Ϸ8%) in Rich et al. (4) , further studies in extant African great ape populations are needed to assess the true distribution and virulence of P. reichenowi.
What are the practical implications? Considering how cowpox vaccination provides immunity against smallpox, is it possible that vaccination with P. reichenowi sporozoites or merozoites might give humans cross-immunity against P. falciparum? Indeed, might this already have occurred as a ''natural experiment'' in parts of Africa where both parasites and hosts coexist? Perhaps some humans living near ape habitats will have detectable antibodies specific for P. reichenowi, caused by abortive infections? If so, are such humans protected against P. falciparum?
Finally, Rich et al. (4) demonstrate the importance of noninvasive studies of wild and captive chimpanzee populations for understanding disease. There are currently Ͼ24 chimpanzee field research sites and 16 African sanctuaries housing Ͼ1,000 apes. These populations offer precious opportunities for studying uniquely human and chimpanzee diseases. Meanwhile, many of these sites are in dire need of financial and logistical support to which the biomedical research community could contribute. This is an example where all concerned stand to benefit from new knowledge. For example, surveillance of wild chimpanzee populations by veterinarians such as the Cote d'Ivoire site, where the World Health Organization is monitoring Ebola virus has resulted in precious information about the health of wild chimpanzees and the threats they face from anthroponotic pathogens such as measles and respiratory diseases (14) .
Even today, ethically acceptable studies in human volunteers are commonplace, including recent studies of malaria vaccines (1) . In contrast, the conflict between ''ape advocates'' and researchers used to treating chimpanzees as laboratory animals (15) has gone to one extreme, where all research on great apes has been banned in most parts of the world and possibly soon in the United States as well. Considering the crucial need for optimal surveillance and care of both wild and captive chimpanzees, would it not be better to establish ethically acceptable standards for biomedical care and research in these precious populations? Indeed, would it be ethical or rational to ban all future research on humans?
